Day Two

WEDNESDAY, SEPTEMBER 30

8:55 am Chair’s Opemimg Remarks

Challenges With Data & Implementation

9:00 am Panel: Integration Within the Pharmaceutical Community

  • David Anstatt Executive Director, Center for Observational Research & Data Sciences, Bristol-Myers Squibb
  • Michael Lees Head of Value, Evidence and Portfolio Strategy, Takeda
  • Eric Klein Senior Director, Oncology - Global Patient Outcomes and RWE, Eli Lilly and Company

Synopsis

  • Big players in the field discuss their issues in company structure to compare bottlenecks and advantages

9:45 am Strategic Vision for RWE Generation Across the Product Lifecycle

Synopsis

  • Examining evidence generation as a key deliverable and an important strategic capability to enable efficient drug development and commercialization across the product lifecycle
  • Discussing the importance of understanding RWE approaches to address key questions, and an aligned leadership structure that embraces cross-functional trust, collaboration and communication
  • Defining the challenges impeding the full realization of benefit from RWE and opportunities to better ensure that needed evidence is generated

10:15 am Synthea: Augmenting RWD & Synthetic Data into a Limitless Platform

Synopsis

  • Presenting an introduction to Synthea – a synthetic universe
  • Augmenting clinical data for insight discovery
  • Reimagining AI and ML testing with synthetic data

11:00 am Morning Break & Networking

11:30 am Considerations for integrating digital and sensor data into the RWD ecosystem

Synopsis

  • Opportunities and challenges in data generated by remote monitoring systems
  • Augmenting real-world patient data with open-source public data
  • Personalizing RWE with AI

12:00 pm Strategic alignment of the question to the data

Synopsis

  • What are the different types of real world data (EMR, claims, PROs etc), including their uses and limitations
  • What RWE approach is best used for the question at hand

12:30 pm Lunch & Networking

1:30 pm What is Normal? Using AI to Normalize & Control the Quality of Data Outputs

  • Kevin Francis Principal - Head of RWE, Insights & Analytics, Trinity

Synopsis

  • Advanced computing to address the increasingly available and ever-growing big data
  • Different ways to use this technology to improve efficiency and outcomes of research
  • How it can improve business opportunities and drive growth in the future

Optimizing Post-Clinical Commercial Success

2:00 pm Strategizing Market Access – Ensuring Implementation for the Whole of the Drug Development Continuum

Synopsis

  • Comparing the differences between Medical Affairs and Market Access departments
  • Describing the transition from European to global outreach

2:30 pm Afternoon Break & Networking

3:00 pm Global Medical Affairs (GMA): Lessons Learnt from Creating a Department

  • Amy Place Senior Director, Field Medical Affairs, Scholar Rock

Synopsis

  • Revealing the plans and impact of building out a GMA branch
  • Recollecting on current observations and future challenges
  • Detailing personal accounts of introducing and incorporating GMA into trial design

3:30 pm Understanding Market Access Methodology

  • Omar Ali Pharmacist Consultant, QIPP Adviser Payer Network

Synopsis

  • Ensuring real world data effectiveness at other ends of the value chain
  • How to realize the full potential and seize the opportunity RWE presents
  • RWE usage perspectives of pharma and payers and how this will change in the next few years

4:00 pm Chair’s Closing Remarks & End of Conference